BRAF and neoplasm: demonstrated that AMD1, a key enzyme in A375 melanoma responsible for vemurafenib resistance, upregulates polyamine synthesis, thereby increasing mitochondrial activity and promoting resistance (49) Vemurafenib is commonly used to treat melanoma with BRAF V600E mutations, but tumor resistance diminishes its therapeutic efficacy.